Premium
Letter: comparative efficacy of biological therapy in patients with ulcerative colitis – authors’ reply
Author(s) -
Stidham R. W.,
Lee T. C. H.,
Higgins P. D. R.,
Deshpande A. R.,
Sussman D. A.,
Singal A. G.,
Elmunzer B. J.,
Vijan S.,
Saini S. D.,
Waljee A. K.
Publication year - 2014
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.12773
Subject(s) - vedolizumab , medicine , ulcerative colitis , clinical trial , clinical endpoint , disease
ACKNOWLEDGEMENTS We thank Ms. Patricia Erwin, Medical Librarian at the Mayo Clinic Library for helping in the literature search for this systematic review and meta-analysis. Declaration of personal interests: None. Declaration of funding interests: This study was made possible by support from the Center for the Science of Healthcare Delivery, Mayo Clinic and a CTSA Grant UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), as well as the NIH grant EB001981. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Dr Loftus has consulted for and has received research support from Janssen Biotech, AbbVie, UCB Pharma and Takeda.